$35.280
+0.557 (+1.58%)收盘时
AVLN 同业对比
In the context of the broader market, AVLN competes directly with industry leaders such as LBRX and LTGO. With a market capitalization of $1.54B, it holds a leading position in the sector. When comparing efficiency, AVLN's gross margin of N/A stands against LBRX's N/A and LTGO's N/A. Such benchmarking helps identify whether Avalyn Pharma Inc is trading at a premium or discount relative to its financial performance.
Avalyn Pharma Inc 财务表现
Avalyn Pharma has reported increasing net losses, with Q2 2026 showing a net loss of $28.9 million, and a current ratio of 33.12, indicating strong liquidity to cover short-term liabilities.
Financials
FY2026Q2
YoY:
+43.68%
-31.29M
Operating Profit
FY2026Q2
YoY:
+43.31%
-28.93M
Net Income after Tax
FY2026Q2
YoY:
+104.17%
-0.98
EPS - Diluted
FY2026Q2
-26.34M
Free Cash Flow
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。